• Brittle bones have been reported in children, adolescents and adults with cystic fibrosis (CF), independently of sex; this has been termed CFrelated bone disease. In CF patients with the F508del mutation in the Cftr gene, vertebral fractures and the subsequent dorsal kyphosis decrease pulmonary function, thus accelerating the course of the disease and decreasing the quality of life in CF patients.
• Male and female mice with the homozygous F508del mutation in CFTR develop a severe osteopenic phenotype early on (Le Henaff C. et al, 2012).
• Miglustat (N-butyldeoxynojyrimicin), the active ingredient of Zavesca® was reported to normalize sodium and CFTR-dependent chloride transport in primary human F508del CFTR airway cells and in nasal mucosa in F508del CF mice.
• To evaluate the efficacity of oral miglustat treatment on parameters of the bone microarchitecture, histomorphometry and bone formation rate in F508del mice.
Oral administration of miglustat normalizes bone mass by increasing bone formation in F508del mice. This study strongly supports miglustat therapy in patients with CF-related bone disease. 
